Recruiting

Observational Study

Sponsor:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Code:

NCT05930899

Conditions

Cardiovascular Diseases

Aortic Valve Stenosis

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Accepted

Interventions

Genetics

Study Details

Brief summary:

The objective of the TOmAS Biobank is the conservation of biological material (plasma, saliva, and tissue explanted during surgery), genetic material (DNA, RNA, etc.), and clinical data ("material/data") collected from patients with cardiovascular diseases (CVD) as well as from control participants, in order to allow future studies evaluating novel proteomic, transcriptomic and epigenomic markers (as well as other emerging -omic technologies) for CVD (i.e. aortic stenosis, cardiomyopathy, myorcardial infarction, etc). The study of physiological and genetic factors will allow for the discovery of new genomic and other -omic (including proteomic, transcriptomic and epigenomic) biomarkers associated with CVD which will lead to an improved understanding of the underlying biology of CVD and may provide future insights into the prevention and treatment of this type of disease.

Conditions

Cardiovascular Diseases

Aortic Valve Stenosis

Study ID

NCT05930899

Start date

Oct 12, 2017

Status verified date

Nov, 2024

Completion date

Jan 1, 2040

Anticipated

Primary completion date

Jan 1, 2040

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection.
  • Undergoing cardiac surgery for non-aortic valve pathology

Exclusion Criteria:

  • Individuals with Congenital heart disease will be excluded

Study Design

Enrollment

10000 participants

Anticipated

Interventions and Outcome Measures

Arms

CVD Group

CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection.

Control Group

control groups will be defined as:

1. No echocardiographic evidence of AS (or any aortic valve abnormality) and
2. 60 years of age

Interventions

Genetics

TOmAS is a biobank and all patients will be genotyped

Primary outcome measure

  • TOmAS [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

George Thanassoulis, MD

5149341934george.thanassoulis@mcgill.ca

Mireille Roy-Joncas, RN

5149341934mireille.roy-joncas@muhc.mcgill.ca

Locations

Montreal General Hospital

Recruiting

Montréal, Quebec, Canada, H3G 1A4

Contacts

George Thanassoulis, MD

5142340818george.thanassoulis@mcgill.ca

Royal Victoria Hospital

Recruiting

Montréal, Quebec, Canada, H4A 3J1

Contacts

George Thanassoulis, MD

5149341934george.thanassoulis@mcgill.ca

More Information

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Last update posted

Nov 20, 2024

Last verified

Nov, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre on 2024-11-20.